← Back to Clinical Trials
Recruiting NCT07184411

NCT07184411 Activities-based Locomotor Training in Children With Cerebral Palsy

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07184411
Status Recruiting
Phase
Sponsor Baylor University
Condition Cerebral Palsy (CP)
Study Type INTERVENTIONAL
Enrollment 19 participants
Start Date 2026-01-11
Primary Completion 2028-05

Eligibility & Interventions

Sex All sexes
Min Age 2 Years
Max Age 6 Years
Study Type INTERVENTIONAL
Interventions
Activities-based locomotor trainingphysical therapy

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 19 participants in total. It began in 2026-01-11 with a primary completion date of 2028-05.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This project aims to improve the quality of life and functional outcomes for young non-ambulatory children with Cerebral Palsy (CP) by investigating the efficacy of an Activities-Based Locomotor Training (AB-LT) program compared to usual care. By targeting the body structures, activities, and participation components of the World Health Organization's International Classification of Functioning, Disability, and Health (ICF) framework, this study seeks to enhance our understanding of neuroplasticity and motor learning in this population, offering a novel approach to rehabilitation. Results from this research will lead to more effective, individualized therapies that improve motor function, reduce disability, and ultimately lower the long-term healthcare needs associated with CP.

Eligibility Criteria

Inclusion Criteria: To be eligible for this study, the child must be: * • Able to hold their head upright for 5 seconds when supported at the trunk in sitting (the minimal amount of head control necessary for safe walking on the partial body weight support system during the AB-LT intervention); * Non-ambulatory or not walking as primary means of mobility; * Willing to attend the AB-LT intervention at Fortis Therapy Center in Dripping Springs, Texas for 3 hours/ day, 5 days/week, for 3 weeks; and * Willing to commit to a total of 7 weeks of the study, and to continue their usual care during the time period in which they are not enrolled in the AB-LT intervention. Exclusion Criteria: The child must not have: * • Surgery or botulinum toxin injections in the previous 6 months; * Uncontrolled epilepsy; and * Uncontrolled cardiovascular disease

Contact & Investigator

Central Contact

Elizabeth Ardolino, PhD, PT

✉ liz_ardolino@baylor.edu

📞 215-605-9319

Principal Investigator

Elizabeth Ardolino, PhD, PT

PRINCIPAL INVESTIGATOR

Baylor University

Frequently Asked Questions

Who can join the NCT07184411 clinical trial?

This trial is open to participants of all sexes, aged 2 Years or older, up to 6 Years, studying Cerebral Palsy (CP). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07184411 currently recruiting?

Yes, NCT07184411 is actively recruiting participants. Contact the research team at liz_ardolino@baylor.edu for enrollment information.

Where is the NCT07184411 trial being conducted?

This trial is being conducted at Dripping Springs, United States.

Who is sponsoring the NCT07184411 clinical trial?

NCT07184411 is sponsored by Baylor University. The principal investigator is Elizabeth Ardolino, PhD, PT at Baylor University. The trial plans to enroll 19 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology